Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hericium mushroom, specifically referring to the extract of the fungus *Hericium erinaceus* (Lion's Mane), is an approved pharmaceutical product in China, commonly marketed as Houtoujun tablets (猴头菌片). Developed and manufactured by companies such as Shenghua Pharmaceutical Technology, it is primarily indicated for the treatment of gastrointestinal conditions, including chronic gastritis, gastric ulcers, and duodenal ulcers. The therapeutic effect is attributed to its ability to protect and promote the repair of the gastric mucosa, reduce inflammation, and potentially inhibit the growth of *Helicobacter pylori*. Beyond its gastrointestinal applications, *Hericium erinaceus* contains bioactive compounds like hericenones and erinacines that stimulate the synthesis of nerve growth factor (NGF), leading to significant research interest in its neuroprotective and cognitive-enhancing properties.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hericium erinaceus (Jiangsu Shenhua Pharmaceutical).